Suppliers

Take the Right Path Upstream with MilliporeSigma

Take the Right Path Upstream with MilliporeSigma

You are developing a monoclonal antibody and a world of potential is ahead of you. However, your time to realize this potential is limited. You need to act quickly to get your biological drug to market, but have you considered the impact of your decisions as you are developing upstream? Decisions may be difficult to reverse or will require significant backtracking and resources. With our upstream ecosystem, you get your upstream development right the first time.

To successfully advance your molecule from the laboratory to the clinic quickly without sacrificing product quality, process efficiency, or patient safety, you must make the right decisions at the right time; and navigate complexities associated with business planning, cell line development, process development, technology, regulatory and risk assessment.

Our upstream ecosystem—comprised of cell line and media platforms, cell line development, cell line and product characterization services, single-use bioreactors and mixers, process development services, and next generation processing programs—gets upstream development right the first time. Our experts will save you precious time, optimize performance, improve feasibility and sustainability, while laying the groundwork for downstream success.

Related resources

show more

Strategies for Upstream Intensification

Strategies for Upstream Intensification

Take the Right Path Upstream with MilliporeSigma | 01-Sep-2020 | Technical / White Paper

The Facility of the Future represents a transformation in how biologics are developed and manufactured.